Montelukast in chronic lung allograft dysfunction after lung transplantation.
Acetates
/ therapeutic use
Adult
Allografts
Chronic Disease
Cyclopropanes
Cytochrome P-450 CYP1A2 Inducers
/ therapeutic use
Female
Follow-Up Studies
Forced Expiratory Volume
Graft Rejection
/ drug therapy
Humans
Lung Transplantation
/ adverse effects
Male
Middle Aged
Postoperative Period
Quinolines
/ therapeutic use
Retrospective Studies
Sulfides
Transplant Recipients
chronic lung allograft dysfunction
leukotriene receptor antagonist
lung transplantation
montelukast
outcome
treatment
Journal
The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation
ISSN: 1557-3117
Titre abrégé: J Heart Lung Transplant
Pays: United States
ID NLM: 9102703
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
08
12
2017
revised:
26
11
2018
accepted:
30
11
2018
pubmed:
15
1
2019
medline:
12
9
2020
entrez:
15
1
2019
Statut:
ppublish
Résumé
Chronic lung allograft dysfunction (CLAD) is a major cause of post‒lung transplant mortality, with limited medical treatment options. In this study we assessed the association of montelukast treatment with pulmonary function and outcome in lung transplant recipients with progressive CLAD. We performed a retrospective study of all lung transplant recipients transplanted between July 1991 and December 2016 at our center and who were treated for at least 3 months with montelukast for progressive CLAD, despite at least 3 months of prior azithromycin therapy. Main outcome parameters included evolution of pulmonary function and progression-free and overall survival. A total of 153 patients with CLAD (115 with bronchiolitis obliterans syndrome and 38 with restrictive allograft syndrome) were included, of whom 46% had a forced expiratory volume in 1 second (FEV Montelukast was associated with a significant attenuation in rate of FEV
Sections du résumé
BACKGROUND
Chronic lung allograft dysfunction (CLAD) is a major cause of post‒lung transplant mortality, with limited medical treatment options. In this study we assessed the association of montelukast treatment with pulmonary function and outcome in lung transplant recipients with progressive CLAD.
METHODS
We performed a retrospective study of all lung transplant recipients transplanted between July 1991 and December 2016 at our center and who were treated for at least 3 months with montelukast for progressive CLAD, despite at least 3 months of prior azithromycin therapy. Main outcome parameters included evolution of pulmonary function and progression-free and overall survival.
RESULTS
A total of 153 patients with CLAD (115 with bronchiolitis obliterans syndrome and 38 with restrictive allograft syndrome) were included, of whom 46% had a forced expiratory volume in 1 second (FEV
CONCLUSIONS
Montelukast was associated with a significant attenuation in rate of FEV
Identifiants
pubmed: 30638839
pii: S1053-2498(18)31773-X
doi: 10.1016/j.healun.2018.11.014
pii:
doi:
Substances chimiques
Acetates
0
Cyclopropanes
0
Cytochrome P-450 CYP1A2 Inducers
0
Quinolines
0
Sulfides
0
montelukast
MHM278SD3E
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
516-527Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2018 International Society for Heart and Lung Transplantation. Published by Elsevier Inc. All rights reserved.